A historic innovation
Since 1983, Roche has pioneered the advancement of PCR analysis, which is recognized as a gold standard in laboratory diagnostics. The cobas® Liat® PCR System replicates extracted DNA or RNA from patient samples to accurately identify infectious diseases. Using Roche PCR technology, laboratory-quality sensitivity and specificity are achieved across assays, significantly reducing the risk of false negative and false positive results.1
Sensitivity*
Specificity*
Strep A
cobas® Strep A1
Specificity: 93.3%
Sensitivity**
Specificity**
Influenza A
Influenza B
cobas® Influenza A/B2
Specificity: 97.9%
Specificity: 97.9%
Positive agreement†
Negative agreement†
Influenza A
Influenza B
RSV
cobas® Influenza A/B & RSV3
Specificity: 97.9%
Specificity: 97.9%
Sensitivity††
Specificity††
Cdiff
cobas® Cdiff4
Specificity*: 96.4%
Quality without compromise
Patients deserve the best care possible—that means reliable results in a reasonably short amount of time. Current diagnostic options offer a trade-off between speed or accuracy, and since many diseases present similar symptoms at early stages, the need for a reliably accurate point-of-care testing solution is high.
Explore the pros and cons of current diagnostic options
Signs & symptoms
Pro
Quick diagnosis, based on knowledge and experience
Con
Could lead to incorrect antibiotic treatment
On-site rapid antigen test
Pro
Fast results, easy to use
Con
Potentially less accurate, with uncertainty around negative results
Lab cultures
Pro
Highly accurate and definitive
Con
Prolongs time for patient diagnosis
Explore the cobas® Liat® System
*Compared to culture and latex agglutination for Strep A typing; CLIA data.
**Compared to viral culture.
†Compared to an FDA-cleared laboratory based multiplexed real-time reverse transcription PCR (RT-PCR) test; CLIA data.
††Compared to direct culture.
‡Compared to direct and enriched culture.
CI=confidence intervals.
cobas® Strep A, cobas® Influenza A/B and cobas® Influenza A/B & RSV are CE-IVD and FDA 510(k) cleared; CLIA waived. cobas® Cdiff is CE-IVD cleared.
References: 1. cobas® Strep A [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 2. cobas® Influenza A/B [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2015. 3. cobas® Influenza A/B & RSV [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 4. cobas® Cdiff [package insert].